Its downstream targets include anti-apoptotic proteins such as Bcl-2, and MDK also facilitates drug efflux by upregulating ABC transporters, such as MDR1 and ABCG2, leading to multidrug resistance in gastric, leukemia, and ovarian cancer models. This evidence concerns the gene MDK and ovarian cancer.